297 related articles for article (PubMed ID: 22888106)
1. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.
Wagener JS; Rasouliyan L; VanDevanter DR; Pasta DJ; Regelmann WE; Morgan WJ; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):666-73. PubMed ID: 22888106
[TBL] [Abstract][Full Text] [Related]
2. Predictors of pulmonary exacerbation treatment in cystic fibrosis.
Sanders DB; Ostrenga JS; Rosenfeld M; Fink AK; Schechter MS; Sawicki GS; Flume PA; Morgan WJ
J Cyst Fibros; 2020 May; 19(3):407-414. PubMed ID: 31257102
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic treatment of signs and symptoms of pulmonary exacerbations: a comparison by care site.
Schechter MS; Regelmann WE; Sawicki GS; Rasouliyan L; VanDevanter DR; Rosenfeld M; Pasta D; Morgan W; Konstan MW
Pediatr Pulmonol; 2015 May; 50(5):431-40. PubMed ID: 25530325
[TBL] [Abstract][Full Text] [Related]
4. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.
Sanders DB; Solomon GM; Beckett VV; West NE; Daines CL; Heltshe SL; VanDevanter DR; Spahr JE; Gibson RL; Nick JA; Marshall BC; Flume PA; Goss CH;
J Cyst Fibros; 2017 Sep; 16(5):592-599. PubMed ID: 28460885
[TBL] [Abstract][Full Text] [Related]
5. Extending the course of intravenous antibiotics in adult patients with cystic fibrosis with acute pulmonary exacerbations.
Sequeiros IM; Jarad NA
Chron Respir Dis; 2012; 9(4):213-20. PubMed ID: 22637747
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary exacerbations in cystic fibrosis: young children with characteristic signs and symptoms.
Regelmann WE; Schechter MS; Wagener JS; Morgan WJ; Pasta DJ; Elkin EP; Konstan MW;
Pediatr Pulmonol; 2013 Jul; 48(7):649-57. PubMed ID: 22949088
[TBL] [Abstract][Full Text] [Related]
7. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
[No Abstract] [Full Text] [Related]
8. Routine spirometry in cystic fibrosis patients: impact on pulmonary exacerbation diagnosis and FEV1 decline.
Aquino CSB; Rodrigues JC; Silva-Filho LVRFD
J Bras Pneumol; 2022; 48(3):e20210237. PubMed ID: 35674545
[TBL] [Abstract][Full Text] [Related]
9. Clinical Outcomes of Antipseudomonal versus Other Antibiotics among Children with Cystic Fibrosis without
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Nichols DP; Rosenfeld M; Kronman MP
Ann Am Thorac Soc; 2022 Aug; 19(8):1320-1327. PubMed ID: 35289740
[No Abstract] [Full Text] [Related]
10. Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.
Heltshe SL; Goss CH; Thompson V; Sagel SD; Sanders DB; Marshall BC; Flume PA
Thorax; 2016 Mar; 71(3):223-9. PubMed ID: 25911223
[TBL] [Abstract][Full Text] [Related]
11. Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations.
West NE; Beckett VV; Jain R; Sanders DB; Nick JA; Heltshe SL; Dasenbrook EC; VanDevanter DR; Solomon GM; Goss CH; Flume PA;
J Cyst Fibros; 2017 Sep; 16(5):600-606. PubMed ID: 28457954
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic duration and changes in FEV
Espel JC; Palac HL; Cullina JF; Clarke AP; McColley SA; Prickett MH; Jain M
BMC Pulm Med; 2017 Nov; 17(1):160. PubMed ID: 29187171
[TBL] [Abstract][Full Text] [Related]
13. Association of Inhaled Antibiotics in Addition to Standard Intravenous Therapy and Outcomes of Pediatric Inpatient Pulmonary Exacerbations.
Cogen JD; Faino AV; Onchiri F; Hoffman LR; Kronman MP; Nelson M; Nichols DP; Rosenfeld M; VanDevanter DR; Gibson RL
Ann Am Thorac Soc; 2020 Dec; 17(12):1590-1598. PubMed ID: 32726564
[No Abstract] [Full Text] [Related]
14. Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis.
Ryan G; Jahnke N; Remmington T
Cochrane Database Syst Rev; 2012 Dec; 12():CD008319. PubMed ID: 23235659
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic Regimen Changes during Cystic Fibrosis Pediatric Pulmonary Exacerbation Treatment.
Cogen JD; Sanders DB; Slaven JE; Faino AV; Somayaji R; Gibson RL; Hoffman LR; Ren CL
Ann Am Thorac Soc; 2023 Sep; 20(9):1293-1298. PubMed ID: 37327485
[No Abstract] [Full Text] [Related]
16. Oral antimicrobial use in outpatient cystic fibrosis pulmonary exacerbation management: a single-center experience.
Briggs EC; Nguyen T; Wall MA; MacDonald KD
Clin Respir J; 2012 Jan; 6(1):56-64. PubMed ID: 21595857
[TBL] [Abstract][Full Text] [Related]
17. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
[No Abstract] [Full Text] [Related]
18. Effect of Concomitant Azithromycin and Tobramycin Use on Cystic Fibrosis Pulmonary Exacerbation Treatment.
Cogen JD; Faino AV; Onchiri F; Gibson RL; Hoffman LR; Kronman MP; Rosenfeld M; Nichols DP
Ann Am Thorac Soc; 2021 Feb; 18(2):266-272. PubMed ID: 32810412
[No Abstract] [Full Text] [Related]
19. The effect of oral and intravenous antimicrobials on pulmonary exacerbation recovery in cystic fibrosis.
VanDevanter EJ; Heltshe SL; Skalland M; Lechtzin N; Nichols D; Goss CH
J Cyst Fibros; 2021 Nov; 20(6):932-936. PubMed ID: 33685776
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with lung function response with oral antibiotic treatment of pulmonary exacerbations in cystic fibrosis.
Blanchard AC; Shaw M; Ratjen F; Tullis E; Daneman N; Waters V
J Cyst Fibros; 2023 Sep; 22(5):880-883. PubMed ID: 37474423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]